Loading stock…

Healthpeak Properties, Inc. (DOC) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Healthpeak Properties, Inc.

DOCMarket cap $13BPrice $19.0

Country🇺🇸United States

SectorReal Estate

IndustryHealthcare REITs

Owns and leases medical office buildings, life science campuses, and senior housing facilities across the U.S. Its properties sit next to hospitals and research hubs, banking on America's aging population and biotech boom to keep tenants paying rent for decades.

In Bastion Portfolios?

52W Return+7%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+11%7

Revenue Forecast

Rev CAGR (1y)+6%5

Rev CAGR (3y)+6%5

Rev CAGR (5y)+6%5

Earnings Forecast

EPS Growth Y+1+73%10

EPS Growth Y+2-32%2

EPS Growth Y+3+39%9

Quality

Margins

EBIT Margin17%7

Net Income Margin8%5

Free Cash Flow Margin42%10

Debt

Net Debt/EBITDA5.41

Efficiency

ROE3%2

ROA1%3

Earnings Stability22

GEAR+WEAK25

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)1791

P/E Ratio (Forward 3y)1151

P/BV1.77

EV Multiples

EV/EBITDA Fwd144

EV/EBIT Fwd431

Yield

Free Cash Flow Yieldna–

Dividend Yield6.4%10

Momentum

Short term

1 month return-8%3

3 month return-12%3

YTD return+24%8

Mid term

Price vs 52wHigh84%6

1 year return+6%5

Long term

3 year return+34%5

5 year return-25%2

Risk Shield

Price Risk

Beta0.58

Volatility29%7

Free Cash Flow

Free Cash Flow Margin42%10

Free Cash Flow Yieldna–

Quality

ROCE3%2

Earnings Stability22

Net Debt/EBITDA5.41

02Growth

Is it actually growing, and how fast?

DOCHealthpeak Properties

Revenue FY25$2.8B

GROWTH RATING↗

AVERAGE50 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+73%10

EPS growth, FY27E-32%2

EPS growth, FY28E+39%9

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

WATCH

A mid-pack grower, ahead of 50% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 11%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow faster than sales (EPS about 39%/yr vs revenue 6%/yr), so margins should widen. One year dips: EPS falls 32% in year 2.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-12%3

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+6%5

3-year return+34%5

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+24%).

WATCH

It's up 6% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+34% over three years and -25% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%) and over three months (-12%).

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Healthpeak. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

DOCHealthpeak Properties

Revenue FY25$2.8B

GROWTH RATING↗

AVERAGE50 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+11%7

Revenue, next 1Y+6%5

Revenue, next 3Y, CAGR+6%5

Revenue, next 5Y, CAGR+6%5

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+73%10

EPS growth, FY27E-32%2

EPS growth, FY28E+39%9

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 11%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

WATCH

A mid-pack grower, ahead of 50% of companies worldwide.

Revenue is set to grow 6%/yr over the next 3 years, in line with the market.5/10

Revenue grew 11%/yr over the last 3 years; forecasts see it cooling to 6%/yr.

Over five years revenue is set to grow 6%/yr, about average versus companies worldwide.5/10

Earnings are set to grow faster than sales (EPS about 39%/yr vs revenue 6%/yr), so margins should widen. One year dips: EPS falls 32% in year 2.

WEAKNESSES

None flagged.

BOTTOM LINE

Margin Expander

A middle-of-the-pack grower that is slowing. The one thing to watch: forward revenue growth is only about average.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-8%3

3-month return-12%3

YTD return+24%8

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+6%5

3-year return+34%5

5-year return-25%2

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming so far this year (+24%).

WATCH

It's up 6% over the past year, but 16% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (+34% over three years and -25% over five), behind 60% of the market.

The stock is underperforming over the past month (-8%) and over three months (-12%).

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Healthpeak. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community